Harold Bernstein exits BioMarin and enters Maze

14 October 2022

After just a year in the role of chief medical officer and head of global clinical development at Californian biotech BioMarin (Nasdaq: BMRN), Harold Bernstein has taken a new job elsewhere.

Dr Bernstein has been named president, head of R&D and chief medical officer at Maze Therapeutics, a company translating genetic insights into new precision medicines.

Maze, which is based across the bridge from BioMarin in South San Francisco, has also promoted Eric Green, formerly the firm’s senior vice president, research and translational sciences, to the role of chief scientific officer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK